KSKazuko Suzuki

Kazuko Suzuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kazuko Suzuki has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Tsuneo Konta

    Department of Public Health and Hygiene, Yamagata University Graduate School of Medicine, Yamagata, Japan

    16 shared publications
  • Kazunobu Ichikawa

    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2, Iida-Nishi, Yamagata, 990-9585, Japan

    15 shared publications
  • Isao Kubota

    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2, Iida-Nishi, Yamagata, 990-9585, Japan

    14 shared publications
  • Takeo Kato

    Global COE, Yamagata University School of Medicine, Yamagata, Japan

    11 shared publications
  • Ami Ikeda

    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan

    10 shared publications
  • Yoko Shibata

    Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2, Iida-Nishi, Yamagata, 990-9585, Japan

    9 shared publications

Latest Publications

  • Open Access

    Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan

    by Masashi Takano, Kazuko Suzuki, Sakiyo Tsukamoto, Yasuo Nakajima, Hirofumi Ozeki, Masao Yarita, Ai Hayashi

    HIF-PHI inhibitors, including daprodustat, have expanded treatment options for patients with renal anaemia in Japan. This analysis examines real-world utilization of daprodustat in Japan, for which data are currently lacking. This retrospective cohort study analyzed patient characteristics, treatment patterns, and management of renal anaemia in individuals aged >15 years who were treated with daprodustat between 1 August 2020 and 1 July 2023 using an anonymized electronic medical record database. Patients were assigned to dialysis-dependent (DD) and nondialysis-dependent (ND) cohorts. This study included 1299 patients (111 DD cohort; 1188 ND cohort). Mean age was 71.0 and 79.2 years in the DD and ND cohorts, respectively. In both cohorts, hypertension, heart failure, oesophageal gastric erosion, and type 2 diabetes mellitus were frequent comorbidities. In the DD cohort, 31.5% of patients had Hb levels of 9-10 g/dL at baseline and in the ND cohort 35.9% had Hb levels n = 23; Wilcoxon sign-ranked test [WSRT] p = 0.0148) and from 9.6 g/dL at baseline to 10.4 g/dL in the ND cohort (n = 92; WSRT p < 0.0001) 28 weeks after daprodustat initiation. Approximately a third (DD) to almost half (ND) of patients with renal anaemia were not receiving treatment for anaemia. An increase in haemoglobin levels was observed after initiation of daprodustat, including in patients previously treated with erythropoiesis-stimulating agents, however causality cannot be confirmed due to lack of a control group.

  • Open Access

    Tacrolimus use and renal function in pregnancy with lupus nephritis: Analysis of post-marketing surveillance data in Japan

    by Kazuko Suzuki, Satoshi Uno, Naoko Wakasugi

    Objectives: Tacrolimus may be administered to pregnant women with lupus nephritis in Japan if considered therapeutically beneficial, but supporting data are limited. We assessed the safety and effectiveness of tacrolimus before, during, and after pregnancy in women with lupus nephritis receiving tacrolimus. Methods: This was an ad hoc analysis of data from a post-marketing surveillance study of tacrolimus in patients with lupus nephritis in Japan. Pregnancy outcomes, nephritis status, and adverse events were assessed for up to 2 years postpartum. Results: Data were available for 23 births in 21 patients (two patients had two births each). Tacrolimus for lupus nephritis was continued during 11 births in nine patients (during and after pregnancy) and discontinued in 12 patients (when pregnancy was known or when approaching delivery). Renal function was generally maintained in patients who gave birth while receiving tacrolimus; however, there were cases of increased urine protein and decreased renal function over 2 years. There were no unexpected adverse events/safety concerns. Conclusions: These data from clinical practice suggest that tacrolimus is a valid treatment option for lupus nephritis in fertile women in Japan and, with careful monitoring, pregnant women with lupus nephritis may continue their tacrolimus treatment.


  • Serum uric acid levels and mortality in the Japanese population: the Yamagata (Takahata) study

    by Keita Kamei, Tsuneo Konta, Kazunobu Ichikawa, Hiroko Sato, Natsuko Suzuki, Asami Kabasawa, Kazuko Suzuki, Atsushi Hirayama, Yoko Shibata, Tetsu Watanabe, et al.

    Background Serum uric acid level is regulated by gender, dietary habit, genetic predisposition, and renal function, and is associated with the development of renal and cardiovascular diseases. This study prospectively investigated the association between serum uric acid levels and mortality in a community-based population. Methods Three thousand four hundred and eighty-seven subjects regardless of the antihyperuricemic medication (45 % male; mean age 62 years old) from the Takahata town in Japan participated in this study and were followed up for 8 years (median 7.5 years). We examined the association between serum uric acid levels at baseline and the all-cause and cardiovascular mortality, respectively, in this population. Results One hundred seventy-nine subjects died during the follow-up period, with 49 deaths attributed to cardiovascular causes. Kaplan–Meier analysis revealed that the all-cause mortality was significantly higher along with the increase in serum uric acid levels at baseline among female (Log-rank P < 0.01), but not male subjects (P = 0.97). Cox-proportional hazard model analysis with adjustment for possible confounders including age, renal function, and comorbidities revealed that hyperuricemia (uric acid ≥7.0 mg/dL) was an independent risk factor for all-cause and cardiovascular mortality, respectively, in female [hazard ratio (HR) 5.92, 95 % confidence interval (CI) 2.10–14.6 for all-cause mortality, and HR 10.7, 95 % CI 1.76–50.2 for cardiovascular mortality], but not male subjects. Conclusion Hyperuricemia was an independent risk for all-cause and cardiovascular mortality in female, but not among the male subjects in a community-based population.


  • Open Access

    Comparison of the predictive ability of albuminuria and dipstick proteinuria for mortality in the Japanese population: the Yamagata (Takahata) study

    by Hiroko Sato, Tsuneo Konta, Kazunobu Ichikawa, Natsuko Suzuki, Asami Kabasawa, Kazuko Suzuki, Atsushi Hirayama, Yoko Shibata, Tetsu Watanabe, Takeo Kato, et al.

    Background Albuminuria and proteinuria are known risk factors for premature death. This study compared the ability of albuminuria and proteinuria to predict mortality in a community-based population. Methods We evaluated the urinary albumin creatinine ratio (ACR) and proteinuria by dipstick at a baseline survey and examined the association between the 7-year mortality and three categories (albuminuria [ACR ≥ 30 mg/g], trace proteinuria, and ≥[1+] proteinuria) in 3446 Japanese subjects at a local health check. Results Albuminuria, ≥trace proteinuria, and ≥(1+) proteinuria were identified in 514 (14.9 %), 290 (8.4 %), and 151 (4.4 %) subjects, respectively. There were 138 deaths during the follow-up period, including 41 cardiovascular deaths. A Kaplan–Meier analysis showed that all-cause mortality significantly increased along with the increase in ACR and proteinuria levels (log-rank P < 0.01). The mortality rate (deaths per 1000 person-year) was higher in subjects with albuminuria (12.8), ≥trace proteinuria (12.6), and ≥(1+) proteinuria (16.2) than in all subjects (6.9). A Cox proportional hazard model analysis showed that all three categories were significant predictors of all-cause mortality in the unadjusted model, although after adjustment for possible confounders, a significant association was observed only with albuminuria. Albuminuria, but not proteinuria, was a significant predictor of cardiovascular mortality in both the unadjusted and adjusted models. Conclusion Albuminuria had a high prevalence and was strongly associated with mortality, as compared with proteinuria by dipstick, suggesting that albuminuria might be a superior predictor of poor prognosis in the Japanese population.


  • Open Access

    Blood Pressure, Proteinuria, and Renal Function Decline: Associations in a Large Community-Based Population

    by Atsushi Hirayama, Tsuneo Konta, Keita Kamei, Kazuko Suzuki, Kazunobu Ichikawa, Shouichi Fujimoto, Kunitoshi Iseki, Toshiki Moriyama, Kunihiro Yamagata, Kazuhiko Tsuruya, et al.

    Hypertension and proteinuria are risk factors for adverse renal outcomes in patients with chronic kidney disease. This study investigated the associations of blood pressure and proteinuria on renal function in a community-based population. We analyzed data from a nationwide database of 141,514 subjects who participated in the annual “Specific Health Check and Guidance in Japan” checkup in 2008 and 2010. The study subjects were aged between 29 and 74 years, and the cohort comprised 40% men. We examined relationships between blood pressure levels, proteinuria at baseline, and the 2-year change in the estimated glomerular filtration rate (eGFR), which was determined using the Japanese equation. After adjusting for possible confounders, the change in the eGFR was inversely correlated with systolic blood pressure (SBP), but not diastolic blood pressure (DBP), at baseline, irrespective of the presence of proteinuria. Compared with the lowest SBP sixtile (≤118mm Hg), eGFRs declined significantly at SBPs ≥ 134mm Hg in subjects with proteinuria, while eGFRs declined significantly at SBPs ≥ 141mm Hg in those without proteinuria. At the same SBPs, renal function decline was faster and the risk for incident renal insufficiency was higher in subjects with proteinuria compared with those without proteinuria. This study showed that a difference in SBP, but not DBP, is independently associated with a rapid eGFR decline in the general Japanese population, and that the association of SBP on the decline of renal function was greater in subjects with proteinuria compared with those without proteinuria.


  • The involvement of environmental factors in the association between serum uric acid and the genotypes of SLC22A12 and ABCG2 in community-based population : Yamagata (Takahata) study.

    by Tsuneo Konta, Keita Kamei, Kazuko Suzuki

    血清尿酸値の調節には,遺伝素因に加えて,生活食事習慣,合併症などの背景因子が関与している.本検討では,2004年に山形県高畠町の地域健康診断を受診した1599名(男性45.1%,平均年齢61.3歳)を対象として,血清尿酸値と尿酸代謝関連遺伝子の一塩基多型SLC22A12(rs505802),ABCG2 (rs2231142)の関連に,背景因子(年齢,性別,高血圧,糖尿病,肥満,飲酒,喫煙,腎機能,脂質異常)が与える影響を横断的に検討した.交絡因子で補正した重回帰分析では,SLC22A12とABCG2各遺伝子多型と血清尿酸値の関連は,腎機能正常群(推定GFR 60mL/分/1.73m2以上)では有意であったが,腎機能低下群では有意ではなかった.性別では,男性において各遺伝子多型と血清尿酸値の関連がより強かった.また,ABCG2遺伝子多型は喫煙と有意な交互作用を認め,喫煙群で遺伝子多型と血清尿酸の関連が強かった.本検討結果より,日本人地域住民において,尿酸代謝関連遺伝子SLC22A12とABCG2の一塩基多型は血清尿酸値の独立した関連因子であり,その関連性には,腎機能,性別,喫煙などの背景因子が影響することが示唆された.

  • Open Access

    A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population

    by Keita Kamei, Tsuneo Konta, Atsushi Hirayama, Kazuko Suzuki, Kazunobu Ichikawa, Shouichi Fujimoto, Kunitoshi Iseki, Toshiki Moriyama, Kunihiro Yamagata, Kazuhiko Tsuruya, et al.

    Hyperuricemia is a risk factor for adverse renal outcomes in patients with chronic kidney disease. This study investigated the effect of uric acid on renal function in a community-based population. We used a nationwide database of 165 847 subjects (aged 29–74, male 40%) who participated in the annual ‘Specific Health Check and Guidance in Japan’ checkup between 2008 and 2010; we examined the relationship between serum uric acid levels at baseline and 2-year change in the estimated glomerular filtration rate (eGFR) obtained by using the Japanese equation. After adjusting for possible confounders, the eGFR change was inversely correlated with uric acid at baseline. In the multivariable analysis, the decline in eGFR was significantly more rapid in subjects with the slight increase in uric acid (males ≥5.7 mg/dL, females ≥4.4 mg/dL), and the risk for incidental renal insufficiency (eGFR 2) was increased at uric acid of ≥6.3 mg/dL in males and ≥5.5 mg/dL in females, compared with the lowest quintile. The multiple linear regression analysis revealed that the effect of uric acid on eGFR changes was significant, especially in females, those with proteinuria and diabetes and those without alcohol consumption. This study showed that serum uric acid is independently associated with a more rapid decline of eGFR and incident renal insufficiency, and that a slight increase within the normal range of serum uric acid might be a risk for renal damage in the general population.


  • A microarray analysis of urinary microRNAs in renal diseases

    by Tsuneo Konta, Kazunobu Ichikawa, Kazuko Suzuki, Kosuke Kudo, Hiroko Satoh, Keita Kamei, Emiko Nishidate, Isao Kubota

    MicroRNAs (miRNAs), a family of endogenous small non-coding RNAs, are associated with the development of renal diseases. To clarify whether urinary miRNAs (UmiRNAs) can be used for the evaluation of renal disease, we examined the profiles of UmiRNAs in various renal diseases.


  • Albuminuria is an independent predictor of all-cause and cardiovascular mortality in the Japanese population: the Takahata study

    by Tsuneo Konta, Kosuke Kudo, Hiroko Sato, Kazunobu Ichikawa, Ami Ikeda, Kazuko Suzuki, Atsushi Hirayama, Yoko Shibata, Tetsu Watanabe, Makoto Daimon, et al.

    Background Albuminuria is a known risk factor for cardiovascular events and premature deaths. However, the association between urinary albumin excretion and mortality is unknown in the Japanese population. To clarify this, we conducted a community-based longitudinal study. Methods This study included 3,445 registered Japanese subjects (mean age 62.6 years), with a 7-year follow-up. Albuminuria was defined as a urine albumin-creatinine ratio (ACR) ≥30 mg/g in the morning spot urine. Results Subjects with albuminuria (n = 514, 14.9 %) were older and showed a higher prevalence of hypertension, obesity, and diabetes and lower values of estimated glomerular filtration rate (eGFR) than those without albuminuria (n = 2931, 85.1 %). During the follow-up, 138 subjects died. A Kaplan–Meier analysis showed that all-cause mortality significantly increased along with the increase in urine albumin excretion (log-rank test, P < 0.001). The subjects with albuminuria showed a significantly higher mortality rate than those without albuminuria (7.4 vs. 3.4 %; log-rank test, P < 0.001). A Cox proportional hazard model analysis after adjusting for possible confounders showed that albuminuria was an independent risk factor for all-cause and cardiovascular mortality (hazard ratio [HR] 1.69, 95 % confidence interval [CI] 1.12–2.56 and HR 2.27, 95 % CI 1.10–4.70, respectively) but not for noncardiovascular mortality. These associations were preserved after excluding subjects with high ACR (≥300 mg/g). Conclusions Albuminuria was a risk factor for all-cause and cardiovascular mortality in the Japanese population. To detect subjects with a high risk for premature death, measuring urinary albumin excretion might be useful.


  • Rapid decline in renal function after acute myocardial infarction

    by Yusuke Mashima, Tsuneo Konta, Kazunobu Ichikawa, Ami Ikeda, Kazuko Suzuki, Masahiro Wanezaki, Satoshi Nishiyama, Tetsu Watanabe, Isao Kubota

    To investigate the long term effects of cardiac events on renal function, a prospective study of patients with acute myocardial infarction was conducted. A total of 137 patients with acute myocardial infarction were followed for 1 year. The change of estimated glomerular filtration rate (eGFR) in cardiac patients was compared with that in background-matched controls, and the factors associated with eGFR changes were analyzed. The eGFR decrease was much larger after myocardial infarction, from 73.7 ± 1.9 ml/min/1.73 m2 (mean ± SEM) at baseline to 64.7 ± 1.7 at 1 year, (p < 0.001), compared with that of controls (from 72.8 ± 1.2 to 72.1 ± 1.3, p = 0.305). Multiple regression analysis showed that eGFR change was associated negatively with age, baseline eGFR, proteinuria, and positively with the administration of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, but not the severity of cardiac damage and comorbidities. Longitudinal analysis 1 year before and 2 years after myocardial infarction showed that eGFR decrease was larger during baseline and 6 months after the event (-7.0 ± 1.0). Renal decline was rapid after myocardial infarction and was affected by clinical characteristics of patients. Careful follow-up of renal function is recommended to prevent the progression of renal and cardiac disease.